Global Radiopharmaceuticals for Diagnosis Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Radiopharmaceuticals for Diagnosis market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Radiopharmaceuticals for Diagnosis include Atom High-tech Co., Ltd., Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory, Tianjin Said Biopharmaceutical Co., Ltd., Shenzhen Larven Bioengineering Technology Co., Ltd., Shanghai Atom Kexing Pharmaceutical Co., Ltd., Shanghai Xinke Pharmaceutical Co., Ltd., Ningbo Jun'an Pharmaceutical Technology Co., Ltd., Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. and Guangdong Xi'ai Pharmaceutical Co., Ltd., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Radiopharmaceuticals for Diagnosis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Radiopharmaceuticals for Diagnosis, also provides the sales of main regions and countries. Of the upcoming market potential for Radiopharmaceuticals for Diagnosis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Radiopharmaceuticals for Diagnosis sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Radiopharmaceuticals for Diagnosis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Radiopharmaceuticals for Diagnosis sales, projected growth trends, production technology, application and end-user industry.
Radiopharmaceuticals for Diagnosis Segment by Company
Atom High-tech Co., Ltd.
Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory
Tianjin Said Biopharmaceutical Co., Ltd.
Shenzhen Larven Bioengineering Technology Co., Ltd.
Shanghai Atom Kexing Pharmaceutical Co., Ltd.
Shanghai Xinke Pharmaceutical Co., Ltd.
Ningbo Jun'an Pharmaceutical Technology Co., Ltd.
Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd.
Guangdong Xi'ai Pharmaceutical Co., Ltd.
Chengdu Zhonghe Gaotong Isotope Co., Ltd.
Chengdu Yunke Pharmaceutical Co., Ltd.
Chengdu Xinke Pharmaceutical Co., Ltd.
Beijing Zhibo High-tech Biotechnology Co., Ltd.
RadioMedix, Inc.
PDRadiopharma Inc.
Lantheus
Jubilant Radiopharma
GE Healthcare Ltd
DOE IP
Radiopharmaceuticals for Diagnosis Segment by Type
Strontium [89Sr] Chloride
Sodium Iodide [131I]
Iodine [125I] Sealed Seed Source
Technetium [99mTc] Pentetate
Technetium [99mTc] Polymerized Albumin
Technetium [99mTc] Dithiodithiocarbamate
Other
Radiopharmaceuticals for Diagnosis Segment by Application
Hospital
Clinic
Other
Radiopharmaceuticals for Diagnosis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals for Diagnosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals for Diagnosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals for Diagnosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Radiopharmaceuticals for Diagnosis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Radiopharmaceuticals for Diagnosis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Radiopharmaceuticals for Diagnosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Radiopharmaceuticals for Diagnosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Radiopharmaceuticals for Diagnosis market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Radiopharmaceuticals for Diagnosis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Radiopharmaceuticals for Diagnosis include Atom High-tech Co., Ltd., Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory, Tianjin Said Biopharmaceutical Co., Ltd., Shenzhen Larven Bioengineering Technology Co., Ltd., Shanghai Atom Kexing Pharmaceutical Co., Ltd., Shanghai Xinke Pharmaceutical Co., Ltd., Ningbo Jun'an Pharmaceutical Technology Co., Ltd., Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. and Guangdong Xi'ai Pharmaceutical Co., Ltd., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Radiopharmaceuticals for Diagnosis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Radiopharmaceuticals for Diagnosis, also provides the sales of main regions and countries. Of the upcoming market potential for Radiopharmaceuticals for Diagnosis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Radiopharmaceuticals for Diagnosis sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Radiopharmaceuticals for Diagnosis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Radiopharmaceuticals for Diagnosis sales, projected growth trends, production technology, application and end-user industry.
Radiopharmaceuticals for Diagnosis Segment by Company
Atom High-tech Co., Ltd.
Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory
Tianjin Said Biopharmaceutical Co., Ltd.
Shenzhen Larven Bioengineering Technology Co., Ltd.
Shanghai Atom Kexing Pharmaceutical Co., Ltd.
Shanghai Xinke Pharmaceutical Co., Ltd.
Ningbo Jun'an Pharmaceutical Technology Co., Ltd.
Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd.
Guangdong Xi'ai Pharmaceutical Co., Ltd.
Chengdu Zhonghe Gaotong Isotope Co., Ltd.
Chengdu Yunke Pharmaceutical Co., Ltd.
Chengdu Xinke Pharmaceutical Co., Ltd.
Beijing Zhibo High-tech Biotechnology Co., Ltd.
RadioMedix, Inc.
PDRadiopharma Inc.
Lantheus
Jubilant Radiopharma
GE Healthcare Ltd
DOE IP
Radiopharmaceuticals for Diagnosis Segment by Type
Strontium [89Sr] Chloride
Sodium Iodide [131I]
Iodine [125I] Sealed Seed Source
Technetium [99mTc] Pentetate
Technetium [99mTc] Polymerized Albumin
Technetium [99mTc] Dithiodithiocarbamate
Other
Radiopharmaceuticals for Diagnosis Segment by Application
Hospital
Clinic
Other
Radiopharmaceuticals for Diagnosis Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals for Diagnosis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals for Diagnosis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals for Diagnosis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Radiopharmaceuticals for Diagnosis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Radiopharmaceuticals for Diagnosis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Radiopharmaceuticals for Diagnosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Radiopharmaceuticals for Diagnosis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
198 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Radiopharmaceuticals for Diagnosis Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Radiopharmaceuticals for Diagnosis Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Radiopharmaceuticals for Diagnosis Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Radiopharmaceuticals for Diagnosis Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Radiopharmaceuticals for Diagnosis Market Dynamics
- 2.1 Radiopharmaceuticals for Diagnosis Industry Trends
- 2.2 Radiopharmaceuticals for Diagnosis Industry Drivers
- 2.3 Radiopharmaceuticals for Diagnosis Industry Opportunities and Challenges
- 2.4 Radiopharmaceuticals for Diagnosis Industry Restraints
- 3 Radiopharmaceuticals for Diagnosis Market by Manufacturers
- 3.1 Global Radiopharmaceuticals for Diagnosis Revenue by Manufacturers (2020-2025)
- 3.2 Global Radiopharmaceuticals for Diagnosis Sales by Manufacturers (2020-2025)
- 3.3 Global Radiopharmaceuticals for Diagnosis Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Radiopharmaceuticals for Diagnosis Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Radiopharmaceuticals for Diagnosis Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Radiopharmaceuticals for Diagnosis Manufacturers, Product Type & Application
- 3.7 Global Radiopharmaceuticals for Diagnosis Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Radiopharmaceuticals for Diagnosis Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Radiopharmaceuticals for Diagnosis Players Market Share by Revenue in 2024
- 3.8.3 2024 Radiopharmaceuticals for Diagnosis Tier 1, Tier 2, and Tier 3
- 4 Radiopharmaceuticals for Diagnosis Market by Type
- 4.1 Radiopharmaceuticals for Diagnosis Type Introduction
- 4.1.1 Strontium [89Sr] Chloride
- 4.1.2 Sodium Iodide [131I]
- 4.1.3 Iodine [125I] Sealed Seed Source
- 4.1.4 Technetium [99mTc] Pentetate
- 4.1.5 Technetium [99mTc] Polymerized Albumin
- 4.1.6 Technetium [99mTc] Dithiodithiocarbamate
- 4.1.7 Other
- 4.2 Global Radiopharmaceuticals for Diagnosis Sales by Type
- 4.2.1 Global Radiopharmaceuticals for Diagnosis Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Radiopharmaceuticals for Diagnosis Sales by Type (2020-2031)
- 4.2.3 Global Radiopharmaceuticals for Diagnosis Sales Market Share by Type (2020-2031)
- 4.3 Global Radiopharmaceuticals for Diagnosis Revenue by Type
- 4.3.1 Global Radiopharmaceuticals for Diagnosis Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Radiopharmaceuticals for Diagnosis Revenue by Type (2020-2031)
- 4.3.3 Global Radiopharmaceuticals for Diagnosis Revenue Market Share by Type (2020-2031)
- 5 Radiopharmaceuticals for Diagnosis Market by Application
- 5.1 Radiopharmaceuticals for Diagnosis Application Introduction
- 5.1.1 Hospital
- 5.1.2 Clinic
- 5.1.3 Other
- 5.2 Global Radiopharmaceuticals for Diagnosis Sales by Application
- 5.2.1 Global Radiopharmaceuticals for Diagnosis Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Radiopharmaceuticals for Diagnosis Sales by Application (2020-2031)
- 5.2.3 Global Radiopharmaceuticals for Diagnosis Sales Market Share by Application (2020-2031)
- 5.3 Global Radiopharmaceuticals for Diagnosis Revenue by Application
- 5.3.1 Global Radiopharmaceuticals for Diagnosis Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Radiopharmaceuticals for Diagnosis Revenue by Application (2020-2031)
- 5.3.3 Global Radiopharmaceuticals for Diagnosis Revenue Market Share by Application (2020-2031)
- 6 Global Radiopharmaceuticals for Diagnosis Sales by Region
- 6.1 Global Radiopharmaceuticals for Diagnosis Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Radiopharmaceuticals for Diagnosis Sales by Region (2020-2031)
- 6.2.1 Global Radiopharmaceuticals for Diagnosis Sales by Region (2020-2025)
- 6.2.2 Global Radiopharmaceuticals for Diagnosis Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Radiopharmaceuticals for Diagnosis Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Radiopharmaceuticals for Diagnosis Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Radiopharmaceuticals for Diagnosis Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Radiopharmaceuticals for Diagnosis Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Radiopharmaceuticals for Diagnosis Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Radiopharmaceuticals for Diagnosis Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Radiopharmaceuticals for Diagnosis Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Radiopharmaceuticals for Diagnosis Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Radiopharmaceuticals for Diagnosis Revenue by Region
- 7.1 Global Radiopharmaceuticals for Diagnosis Revenue by Region
- 7.1.1 Global Radiopharmaceuticals for Diagnosis Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Radiopharmaceuticals for Diagnosis Revenue by Region (2020-2025)
- 7.1.3 Global Radiopharmaceuticals for Diagnosis Revenue by Region (2026-2031)
- 7.1.4 Global Radiopharmaceuticals for Diagnosis Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Radiopharmaceuticals for Diagnosis Revenue (2020-2031)
- 7.2.2 North America Radiopharmaceuticals for Diagnosis Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Radiopharmaceuticals for Diagnosis Revenue (2020-2031)
- 7.3.2 Europe Radiopharmaceuticals for Diagnosis Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Radiopharmaceuticals for Diagnosis Revenue (2020-2031)
- 7.4.2 Asia-Pacific Radiopharmaceuticals for Diagnosis Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Radiopharmaceuticals for Diagnosis Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Radiopharmaceuticals for Diagnosis Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Atom High-tech Co., Ltd.
- 8.1.1 Atom High-tech Co., Ltd. Comapny Information
- 8.1.2 Atom High-tech Co., Ltd. Business Overview
- 8.1.3 Atom High-tech Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Atom High-tech Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.1.5 Atom High-tech Co., Ltd. Recent Developments
- 8.2 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory
- 8.2.1 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Comapny Information
- 8.2.2 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Business Overview
- 8.2.3 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.2.5 Wuxi Jiangyuan Industrial Technology and Trade Co., Ltd. Jiangyuan Pharmaceutical Factory Recent Developments
- 8.3 Tianjin Said Biopharmaceutical Co., Ltd.
- 8.3.1 Tianjin Said Biopharmaceutical Co., Ltd. Comapny Information
- 8.3.2 Tianjin Said Biopharmaceutical Co., Ltd. Business Overview
- 8.3.3 Tianjin Said Biopharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Tianjin Said Biopharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.3.5 Tianjin Said Biopharmaceutical Co., Ltd. Recent Developments
- 8.4 Shenzhen Larven Bioengineering Technology Co., Ltd.
- 8.4.1 Shenzhen Larven Bioengineering Technology Co., Ltd. Comapny Information
- 8.4.2 Shenzhen Larven Bioengineering Technology Co., Ltd. Business Overview
- 8.4.3 Shenzhen Larven Bioengineering Technology Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Shenzhen Larven Bioengineering Technology Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.4.5 Shenzhen Larven Bioengineering Technology Co., Ltd. Recent Developments
- 8.5 Shanghai Atom Kexing Pharmaceutical Co., Ltd.
- 8.5.1 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Comapny Information
- 8.5.2 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Business Overview
- 8.5.3 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.5.5 Shanghai Atom Kexing Pharmaceutical Co., Ltd. Recent Developments
- 8.6 Shanghai Xinke Pharmaceutical Co., Ltd.
- 8.6.1 Shanghai Xinke Pharmaceutical Co., Ltd. Comapny Information
- 8.6.2 Shanghai Xinke Pharmaceutical Co., Ltd. Business Overview
- 8.6.3 Shanghai Xinke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Shanghai Xinke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.6.5 Shanghai Xinke Pharmaceutical Co., Ltd. Recent Developments
- 8.7 Ningbo Jun'an Pharmaceutical Technology Co., Ltd.
- 8.7.1 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Comapny Information
- 8.7.2 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Business Overview
- 8.7.3 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.7.5 Ningbo Jun'an Pharmaceutical Technology Co., Ltd. Recent Developments
- 8.8 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd.
- 8.8.1 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Comapny Information
- 8.8.2 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Business Overview
- 8.8.3 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.8.5 Guangzhou Atom High-tech Isotope Pharmaceutical Co., Ltd. Recent Developments
- 8.9 Guangdong Xi'ai Pharmaceutical Co., Ltd.
- 8.9.1 Guangdong Xi'ai Pharmaceutical Co., Ltd. Comapny Information
- 8.9.2 Guangdong Xi'ai Pharmaceutical Co., Ltd. Business Overview
- 8.9.3 Guangdong Xi'ai Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 Guangdong Xi'ai Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.9.5 Guangdong Xi'ai Pharmaceutical Co., Ltd. Recent Developments
- 8.10 Chengdu Zhonghe Gaotong Isotope Co., Ltd.
- 8.10.1 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Comapny Information
- 8.10.2 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Business Overview
- 8.10.3 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.10.5 Chengdu Zhonghe Gaotong Isotope Co., Ltd. Recent Developments
- 8.11 Chengdu Yunke Pharmaceutical Co., Ltd.
- 8.11.1 Chengdu Yunke Pharmaceutical Co., Ltd. Comapny Information
- 8.11.2 Chengdu Yunke Pharmaceutical Co., Ltd. Business Overview
- 8.11.3 Chengdu Yunke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.11.4 Chengdu Yunke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.11.5 Chengdu Yunke Pharmaceutical Co., Ltd. Recent Developments
- 8.12 Chengdu Xinke Pharmaceutical Co., Ltd.
- 8.12.1 Chengdu Xinke Pharmaceutical Co., Ltd. Comapny Information
- 8.12.2 Chengdu Xinke Pharmaceutical Co., Ltd. Business Overview
- 8.12.3 Chengdu Xinke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.12.4 Chengdu Xinke Pharmaceutical Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.12.5 Chengdu Xinke Pharmaceutical Co., Ltd. Recent Developments
- 8.13 Beijing Zhibo High-tech Biotechnology Co., Ltd.
- 8.13.1 Beijing Zhibo High-tech Biotechnology Co., Ltd. Comapny Information
- 8.13.2 Beijing Zhibo High-tech Biotechnology Co., Ltd. Business Overview
- 8.13.3 Beijing Zhibo High-tech Biotechnology Co., Ltd. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.13.4 Beijing Zhibo High-tech Biotechnology Co., Ltd. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.13.5 Beijing Zhibo High-tech Biotechnology Co., Ltd. Recent Developments
- 8.14 RadioMedix, Inc.
- 8.14.1 RadioMedix, Inc. Comapny Information
- 8.14.2 RadioMedix, Inc. Business Overview
- 8.14.3 RadioMedix, Inc. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.14.4 RadioMedix, Inc. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.14.5 RadioMedix, Inc. Recent Developments
- 8.15 PDRadiopharma Inc.
- 8.15.1 PDRadiopharma Inc. Comapny Information
- 8.15.2 PDRadiopharma Inc. Business Overview
- 8.15.3 PDRadiopharma Inc. Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.15.4 PDRadiopharma Inc. Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.15.5 PDRadiopharma Inc. Recent Developments
- 8.16 Lantheus
- 8.16.1 Lantheus Comapny Information
- 8.16.2 Lantheus Business Overview
- 8.16.3 Lantheus Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.16.4 Lantheus Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.16.5 Lantheus Recent Developments
- 8.17 Jubilant Radiopharma
- 8.17.1 Jubilant Radiopharma Comapny Information
- 8.17.2 Jubilant Radiopharma Business Overview
- 8.17.3 Jubilant Radiopharma Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.17.4 Jubilant Radiopharma Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.17.5 Jubilant Radiopharma Recent Developments
- 8.18 GE Healthcare Ltd
- 8.18.1 GE Healthcare Ltd Comapny Information
- 8.18.2 GE Healthcare Ltd Business Overview
- 8.18.3 GE Healthcare Ltd Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.18.4 GE Healthcare Ltd Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.18.5 GE Healthcare Ltd Recent Developments
- 8.19 DOE IP
- 8.19.1 DOE IP Comapny Information
- 8.19.2 DOE IP Business Overview
- 8.19.3 DOE IP Radiopharmaceuticals for Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.19.4 DOE IP Radiopharmaceuticals for Diagnosis Product Portfolio
- 8.19.5 DOE IP Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Radiopharmaceuticals for Diagnosis Value Chain Analysis
- 9.1.1 Radiopharmaceuticals for Diagnosis Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Radiopharmaceuticals for Diagnosis Production Mode & Process
- 9.2 Radiopharmaceuticals for Diagnosis Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Radiopharmaceuticals for Diagnosis Distributors
- 9.2.3 Radiopharmaceuticals for Diagnosis Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
